托法西提尼布在类固醇不耐药的急性严重性结肠炎:一个回顾性分析
Sayan Malakar1, Srikanth Kothalkar1, Umair Shamsul Hoda1
1Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, IND.
托法西替尼 (tofacitinib) 作为一种治疗类固醇耐药性急性严重性结肠炎 (ASUC) 的治疗方法具有前景,大多数患者的反应很快. 需要进一步的研究来确认其长期的有效性和安全性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类固醇耐药性急性严重性结肠炎 (ASUC) 构成了切除术的高风险.
- 目前的治疗方法,如环素和infliximab有限制,包括副作用和成本.
- 简氏激酶 (JAK) 抑制剂代表了一个潜在的口服小分子替代品.
研究的目的:
- 评估托法西提尼布作为ASUC患者的救援疗法的疗效.
- 评估tofacitinib在这个患者群体中的安全性和反应率.
主要方法:
- 对ASUC患者接受托法西提尼布治疗的回顾性分析.
- 纳入标准:对静脉注射皮松无反应的患者.
- 从2021年1月到2023年7月收集的数据.
主要成果:
- 确定了8名ASUC患者,并接受了托法西提尼布治疗.
- 87.5%的患者在5天内对口服托法西提尼布 (10毫克每天两次) 有反应.
- 一名患者需要切除瘤; 一名患者经历了水黄斑复激活.
结论:
- 托法西提尼布是一种潜在的替代救援疗法,用于对类固醇耐药的ASUC.
- 托法西提尼布在ASUC的长期疗效和安全性需要进一步研究.
更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
